Research programme: neurological disorders therapies - GEMACBIOAlternative Names: GEM ALZ; GEM RR
Latest Information Update: 09 Mar 2011
At a glance
- Originator GEMACBIO
- Developer GemacBio
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Alzheimer's disease; Multiple sclerosis
Most Recent Events
- 18 Jul 2005 Preclinical trials in Alzheimer's disease in France (unspecified route)
- 18 Jul 2005 Preclinical trials in Multiple sclerosis in France (unspecified route)